Ciclosporin
Brand names: Neoral, Sandimmun, Capimune, Deximune, Vanquoral
Ciclosporin is a calcineurin-inhibitor immunosuppressant used in rheumatology as a disease-modifying agent for severe rheumatoid arthritis and other autoimmune conditions unresponsive to first-line therapy.
Adult dose
Dose adjustments
Non-transplant indications: if eGFR decreases >25% below baseline on more than one measurement, reduce dose by 25-50%; if decrease exceeds 35%, consider further reduction; discontinue if dose reduction does not improve eGFR within one month. In nephrotic syndrome with impaired renal function, initial dose should not exceed 2.5 mg/kg/day.
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Hypersensitivity to ciclosporin or any excipient
- Combination with products containing Hypericum perforatum (St John's Wort)
- Combination with medicines that are substrates for P-glycoprotein (Pgp) or organic anion transporter proteins (OATP) where elevated plasma concentrations cause serious/life-threatening events, e.g. bosentan, dabigatran etexilate, aliskiren
Side effects
- Renal dysfunction (dose-dependent increase in serum creatinine and urea)
- Tremor and headache (very common)
- Hirsutism
- Hypertension
- Gastrointestinal: diarrhoea, anorexia, nausea, vomiting
- Hyperlipidaemia (very common); leucopenia; hyperuricaemia, hyperkalaemia, hypomagnesaemia
Interactions
- St John's Wort (contraindicated)
- P-glycoprotein / OATP substrates such as bosentan, dabigatran etexilate, aliskiren (contraindicated)
- Substances that interfere with ciclosporin pharmacokinetics may warrant ciclosporin blood-level monitoring in non-transplant indications
Clinical monograph
How it works
It binds cyclophilin and inhibits calcineurin, blocking the transcription of interleukin-2 and other cytokines and thereby suppressing T-lymphocyte activation.
Prescribing in practice
- Nephrotoxic and hypertensive — renal function and blood pressure must be measured before and regularly during treatment, with dose reduction or withdrawal if creatinine rises persistently.
- Numerous interactions occur via CYP3A4 and P-glycoprotein; avoid concurrent live vaccines and minimise other nephrotoxins.
- Prescribe and dispense by brand name because formulations are not interchangeable, and check the SPC for the relevant indication.
Monitoring
Monitor serum creatinine, blood pressure, potassium, liver function, lipids and (where indicated) blood ciclosporin concentrations during therapy.
Counselling the patient
- Report swelling, reduced urine output or persistent headache.
- Avoid grapefruit juice and tell clinicians about all other medicines.
- Use sun protection and attend monitoring appointments.
Evidence & guidelines
Long-standing use is supported by controlled trials and UK guidance for severe refractory inflammatory arthritis.
Reference: NICE TA180; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- Travis Criteria for Severe Ulcerative Colitis · Inflammatory Bowel Disease
- Immune-Related Adverse Events (irAE) -- GI Toxicity Colitis Grading · Oncology-Related GI
- irAE Hepatitis Grading (CTCAE) · Immunotherapy
- DIPSS — Dynamic International Prognostic Scoring System for Myelofibrosis · Cancer Prognosis
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022